Suppr超能文献

微小RNA-150表达增加与非小细胞肺癌的不良预后相关。

Increased expression of microRNA-150 is associated with poor prognosis in non-small cell lung cancer.

作者信息

Yin Qiu-Wei, Sun Xue-Fei, Yang Guo-Tao, Li Xi-Bo, Wu Ming-Sheng, Zhao Jian

机构信息

Department of Thoracic Surgery, Qilu Hospital of Shandong University Jinan 250012, China.

出版信息

Int J Clin Exp Pathol. 2015 Jan 1;8(1):842-6. eCollection 2015.

Abstract

OBJECTIVES

The aim was to evaluate the clinical significance and prognostic value of tissue miR-150 expression in non-small cell lung cancer (NSCLC) patients.

MATERIALS AND METHODS

Quantitative real-time PCR was used to analyze the expression of miR-150. Overall survival (OS) was estimated using the Kaplan-Meier method, and the differences in survival were compared using the log-rank test. A Cox proportional hazards model was used for multivariate analysis.

RESULTS

Mean miR-150 levels were significantly higher in NSCLC tissues compared with matched non-cancerous tissues (4.07 ± 2.33 vs. 1.00 ± 0.46, P < 0.0001). The level of miR-150 in NSCLC was strongly correlated with lymph node metastasis (P = 0.04), distant metastasis (P = 0.01) and clinical TNM stage (P = 0.02). Kaplan-Meier analysis showed that the cumulative 5-year OS rate was 40.8% in the high expression group, and 69.2% in the low expression group. The log-rank test showed that the OS rate of patients with high miR-150 expression was significantly poorer than that of the remaining cases (P = 0.007).

CONCLUSION

Our data indicated that overexpression of miR-150 in NSCLC tissues has prognostic value.

摘要

目的

评估组织中miR-150表达在非小细胞肺癌(NSCLC)患者中的临床意义及预后价值。

材料与方法

采用定量实时聚合酶链反应分析miR-150的表达。采用Kaplan-Meier法估计总生存期(OS),并使用对数秩检验比较生存差异。采用Cox比例风险模型进行多因素分析。

结果

与配对的癌旁组织相比,NSCLC组织中miR-150的平均水平显著更高(4.07±2.33对1.00±0.46,P<0.0001)。NSCLC中miR-150的水平与淋巴结转移(P=0.04)、远处转移(P=0.01)及临床TNM分期(P=0.02)密切相关。Kaplan-Meier分析显示,高表达组的5年累积总生存率为40.8%,低表达组为69.2%。对数秩检验显示,miR-150高表达患者的总生存率显著低于其余患者(P=0.007)。

结论

我们的数据表明,NSCLC组织中miR-150的过表达具有预后价值。

相似文献

引用本文的文献

6
The P2X7 purinergic receptor: a potential therapeutic target for lung cancer.P2X7 嘌呤能受体:肺癌的潜在治疗靶点。
J Cancer Res Clin Oncol. 2020 Nov;146(11):2731-2741. doi: 10.1007/s00432-020-03379-4. Epub 2020 Sep 5.

本文引用的文献

7
Meta-analysis of microRNA expression in lung cancer.肺癌中 microRNA 表达的荟萃分析。
Int J Cancer. 2013 Jun 15;132(12):2884-93. doi: 10.1002/ijc.27981. Epub 2012 Dec 27.
8
Dysregulation of microRNAs in cancer.癌症中 microRNAs 的失调。
J Biomed Sci. 2012 Oct 17;19(1):90. doi: 10.1186/1423-0127-19-90.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验